{"gene":"FGFRL1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2000,"finding":"FGFRL1 is an integral membrane protein with three extracellular Ig-like domains, a transmembrane segment, and a short intracellular domain that lacks any protein tyrosine kinase domain, distinguishing it from classical FGFRs.","method":"Subtractive cDNA cloning, structural analysis","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — original structural characterization, replicated by multiple subsequent studies","pmids":["11031111"],"is_preprint":false},{"year":2001,"finding":"Recombinant FGFRL1 (FGFR5) ectodomain binds FGF-2 specifically but not FGF-7 or EGF, and with lower affinity than cognate FGFR2C.","method":"Recombinant Fc-fusion protein binding assay","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding assay with recombinant protein, replicated by later studies","pmids":["11418238"],"is_preprint":false},{"year":2003,"finding":"FGFRL1 localizes to the plasma membrane when expressed as a GFP fusion protein in cultured cells, interacts specifically with heparin and FGF2, and exerts a negative effect on cell proliferation when overexpressed in MG-63 osteosarcoma cells, consistent with a decoy receptor function.","method":"GFP fusion live-cell localization, baculovirus recombinant protein production, heparin and FGF2 binding assays, proliferation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods in a single study","pmids":["12813049"],"is_preprint":false},{"year":2007,"finding":"Targeted disruption of the Fgfrl1 gene in mice causes perinatal death due to a significantly reduced diaphragm muscle, demonstrating an essential role of FGFRL1 in diaphragm development.","method":"Targeted gene knockout in mice, histological and molecular analysis","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with specific developmental phenotype, replicated by subsequent studies","pmids":["17986259"],"is_preprint":false},{"year":2007,"finding":"FGFRL1 forms constitutive homodimers at the cell surface as demonstrated by FRET and co-precipitation, and its extracellular domain promotes cell adhesion mediated by heparan sulfate glycosaminoglycans; adhesion is blocked by soluble heparin and reduced by mutagenesis of the heparin-binding site.","method":"FRET, co-precipitation, cell adhesion assay, in vitro mutagenesis","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis and functional assays","pmids":["18061161"],"is_preprint":false},{"year":2008,"finding":"A human FGFRL1 frameshift mutation causing craniosynostosis alters subcellular localization: mutant FGFRL1 is retained predominantly at the plasma membrane rather than in vesicular/Golgi structures as seen for wild-type; two intracellular motifs (tandem tyrosine-based motif and histidine-rich sequence) are responsible for this differential distribution.","method":"Reporter gene assay, subcellular localization by fluorescence microscopy, deletion mutagenesis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 — orthogonal methods including mutagenesis and functional reporter assay with patient mutation","pmids":["19056490"],"is_preprint":false},{"year":2009,"finding":"The FGFRL1 ectodomain is shed from the cell membrane by an unidentified protease. The soluble ectodomain and membrane-bound receptor bind multiple FGF ligands (FGF2, FGF3, FGF4, FGF8, FGF10, FGF22) with high affinity. Ectopic expression of FGFRL1 in Xenopus embryos antagonizes FGFR signaling, supporting a decoy receptor mechanism.","method":"Ligand dot blot, cell-based binding assay, surface plasmon resonance, Xenopus ectopic expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical methods plus in vivo epistasis in Xenopus","pmids":["19920134"],"is_preprint":false},{"year":2009,"finding":"Fgfrl1-deficient mice fail to develop the metanephric kidney due to a dramatic reduction in ureteric branching morphogenesis and lack of mesenchymal-to-epithelial transition; markers Wnt4, Fgf8, Pax8, and Lim1 are absent from the metanephric mesenchyme, and apoptosis is increased in the cortical zone.","method":"Targeted gene knockout, in situ hybridization, marker gene expression analysis, histology","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and molecular phenotype, replicated by subsequent studies","pmids":["19715689"],"is_preprint":false},{"year":2009,"finding":"Targeted deletion of mouse Fgfrl1 recapitulates multiple Wolf-Hirschhorn syndrome phenotypes including craniofacial dysgenesis, skeletal anomalies, congenital heart defects, transient fetal anemia, and a fully penetrant diaphragm defect, establishing Fgfrl1 insufficiency as a contributor to WHS.","method":"Targeted gene knockout in mice, phenotypic analysis","journal":"Disease models & mechanisms","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with comprehensive phenotypic characterization","pmids":["19383940"],"is_preprint":false},{"year":2009,"finding":"The intracellular histidine-rich domain of human FGFRL1 binds zinc, with approximately 2.6 moles zinc per mole protein as measured by atomic absorption; the sea urchin ortholog with a shorter histidine-rich motif binds less zinc (~1.7 mol/mol), indicating evolutionary shaping of a novel zinc-binding domain.","method":"Recombinant protein production, nickel/zinc affinity chromatography, atomic absorption spectroscopy","journal":"BMC biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical measurement of zinc binding with comparative evolutionary analysis","pmids":["20021659"],"is_preprint":false},{"year":2010,"finding":"FGFRL1 induces rapid fusion of cultured cells (CHO, HEK293, HeLa) into large multinucleated syncytia; the Ig3 domain and transmembrane domain are both necessary and sufficient for this fusogenic activity, as demonstrated by luciferase and GFP reporter assays for cytoplasmic mixing.","method":"Overexpression in CHO/HEK293/HeLa cells, luciferase/GFP reporter cytoplasmic mixing assays, domain deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — functional reconstitution with reporter assays and domain mapping","pmids":["20851884"],"is_preprint":false},{"year":2011,"finding":"FGFRL1 binds with its C-terminal histidine-rich domain to Spred1 and other Sprouty/Spred family members (negative regulators of the Ras/Raf/Erk pathway); interaction is via the SPR domain of Spred1, verified by yeast two-hybrid, co-precipitation, and co-distribution at the plasma membrane. Spred1 increases FGFRL1 retention at the plasma membrane.","method":"Yeast two-hybrid, co-precipitation, co-localization in COS1 and HEK293 cells, truncation analysis","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction verified by multiple methods","pmids":["21616146"],"is_preprint":false},{"year":2013,"finding":"In pancreatic beta-cells, FGFRL1 localizes both to the plasma membrane and intracellular insulin secretory granules. It induces ligand-independent ERK1/2 activation via interaction of its intracellular SH2-binding motif with SHP-1 phosphatase; deletion of the histidine-rich domain or full intracellular sequence reduces ERK1/2 activation and shifts localization to the plasma membrane. Overexpression increases cellular insulin content and matrix adhesion.","method":"Fluorescent protein tagging, live-cell imaging, co-immunoprecipitation, domain deletion and point mutation analysis, ERK1/2 phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, mutagenesis, binding partner identification","pmids":["23640895"],"is_preprint":false},{"year":2014,"finding":"FgfrL1-deficient mice lack slow muscle fibers (marked by Myh7, Myl2, Myl3) in the diaphragm and other slow-fiber-rich muscles at E18.5, while fast fiber markers are unaffected; this phenotype is not caused by kidney agenesis, establishing a specific role of FgfrL1 in embryonic slow muscle fiber development.","method":"Gene array, qPCR, in situ hybridization, genetic epistasis (Wnt4 KO comparison)","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — KO phenotype with molecular markers and epistasis control","pmids":["25172430"],"is_preprint":false},{"year":2014,"finding":"Mice lacking the conserved intracellular domain motifs of FgfrL1 (dileucine, tandem tyrosine-based motif YXXΦ, histidine-rich sequence) replaced by GFP are viable, fertile, and phenotypically normal (with only a slight reduction in glomeruli), demonstrating that the extracellular domain, not the intracellular domain, conducts the essential functions of FgfrL1.","method":"Knock-in mouse model (FgfrL1ΔC-GFP), phenotypic analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — clean knock-in with comprehensive phenotypic evaluation","pmids":["25126760"],"is_preprint":false},{"year":2015,"finding":"Cell-cell fusion induced by FGFRL1 requires a hydrophobic site on the Ig3 domain located on a β-sheet within a β-barrel; single amino acid mutations at this site abolish fusion, and soluble Ig1-Ig2-Ig3 or monoclonal antibodies against Ig3 inhibit fusion.","method":"Mutational analysis, inhibition by soluble proteins and antibodies, computer modeling","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis with functional assay, multiple inhibition strategies","pmids":["26025674"],"is_preprint":false},{"year":2016,"finding":"FGFRL1 has no effect on cell proliferation or ERK1/2 activation in overexpression or siRNA knockdown experiments, but promotes cell adhesion during the initial hours after seeding, suggesting it functions as a cell adhesion protein similar to nectins rather than a signaling receptor.","method":"TetOn-inducible overexpression, siRNA knockdown, proliferation assay, Kinexus antibody microarray (250 signaling proteins), cell adhesion assay","journal":"International journal of molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches with gain- and loss-of-function","pmids":["27220341"],"is_preprint":false},{"year":2018,"finding":"FGFR5 (FGFRL1) forms ligand-independent homodimers (~25%) and homotrimers (~75%) at the plasma membrane, and co-expressed with FGFR1 forms heterocomplexes with a 2:1 FGFR5:FGFR1 ratio; upon FGF2 stimulation, these form 4:2 signaling complexes. FGFR5 acts as a co-receptor for FGFR1 and promotes beta-cell survival.","method":"Co-immunoprecipitation, quantitative live-cell imaging (molecular interaction measurements), siRNA knockdown, survival assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus quantitative live-cell imaging, multiple functional assays","pmids":["30217817"],"is_preprint":false},{"year":2020,"finding":"The Ig2 domain of FGFRL1 is the primary binding site for FGF8; all FGFRL1 constructs containing Ig2 interact with FGF8 with high affinity (KD ~2-3 nM by surface plasmon resonance), while constructs lacking Ig2 poorly interact, establishing FGFRL1 as a physiological high-affinity receptor for FGF8.","method":"Recombinant domain expression, ELISA, surface plasmon resonance (Biacore)","journal":"Biomolecules","confidence":"High","confidence_rationale":"Tier 1 — systematic domain dissection with quantitative in vitro binding assays","pmids":["33019532"],"is_preprint":false},{"year":2020,"finding":"FgfrL1 domain-specific knockout mice reveal that the Ig3 domain is essential for metanephric kidney formation (Ig3-deficient mice completely lack kidneys), the Ig2 domain contributes to kidney growth (Ig2-deficient mice have substantially smaller kidneys), and the intracellular domain and Ig1 domain are dispensable for kidney and diaphragm development.","method":"Domain-specific knockout mice, histological and phenotypic analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — systematic domain-deletion mouse genetics with defined organ phenotypes","pmids":["31923383"],"is_preprint":false},{"year":2020,"finding":"FGFRL1 interacts with ENO1 and regulates the ENO1-PI3K/Akt signaling pathway to modulate chemoresistance in small-cell lung cancer; knockdown of FGFRL1 increases chemosensitivity through increased apoptosis and cell cycle arrest.","method":"Co-immunoprecipitation, siRNA knockdown, Western blotting, cell viability assay","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP of binding partner plus functional KD phenotype, single lab","pmids":["31957179"],"is_preprint":false},{"year":2017,"finding":"The fusogenic activity of FGFRL1 Ig3 domain evolved during vertebrate evolution; Ig3 domains from humans, mice, chicken, and fish fuse CHO cells while those from lancelet and sea urchin do not. Mutagenesis of four amino acids in a hydrophobic pocket of the non-fusogenic fish FGFRL1b Ig3 converts it to a fusogenic protein.","method":"Comparative Ig3 domain expression, cell fusion assay, chimeric constructs, in vitro mutagenesis","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional rescue demonstrates specific residues required for fusogenic activity","pmids":["28596102"],"is_preprint":false},{"year":2022,"finding":"Overexpression of FGFR5 (FGFRL1) in beta-cells enhances glucose-stimulated NADPH metabolism and insulin secretion, and increases expression of glycolytic enzymes (GCK, PKM2) and maturity marker UCN3; this response is disrupted by a truncated receptor isoform (R5ΔC) that inhibits the FGFR5/FGFR1 signaling complex, and laminin-induced upregulation of endogenous FGFR5 similarly enhances glucose metabolism.","method":"Genetically encoded NADPH/NADP+ sensor (Apollo-NADP+), overexpression, dominant-negative truncation, insulin secretion assay, transcript analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 — multiple functional assays with orthogonal readouts and dominant-negative validation","pmids":["35414066"],"is_preprint":false}],"current_model":"FGFRL1 is a single-pass transmembrane receptor with three extracellular Ig-like domains that binds FGF ligands (especially FGF2, FGF8) and heparin with high affinity via the Ig2 and Ig3 domains; it lacks an intracellular tyrosine kinase domain and instead carries a histidine-rich zinc-binding tail that interacts with SHP-1 phosphatase and Spred1/Sprouty proteins; it forms constitutive homodimers and can act as a co-receptor for FGFR1 in a 2:1 complex, and its membrane-bound or shed ectodomain can antagonize FGF signaling as a decoy receptor; additionally, its Ig3 domain and transmembrane segment are sufficient to induce cell-cell fusion into multinucleated syncytia through a hydrophobic site in Ig3, and it promotes cell adhesion via heparan sulfate proteoglycans, while being essential in vivo for diaphragm development (particularly slow muscle fibers), metanephric kidney nephrogenesis (primarily through Ig3), and craniofacial/skeletal formation."},"narrative":{"teleology":[{"year":2000,"claim":"Identification of FGFRL1 as a fifth FGFR family member established that a kinase-dead receptor with three Ig domains and a short intracellular tail exists in the FGF signaling system, raising the question of how it functions without catalytic activity.","evidence":"Subtractive cDNA cloning and structural domain analysis","pmids":["11031111"],"confidence":"High","gaps":["No functional data on signaling or biological role","Ligand binding not yet tested","Expression pattern not fully characterized"]},{"year":2001,"claim":"Demonstrating that the FGFRL1 ectodomain binds FGF2 but not FGF7 or EGF established ligand selectivity, showing this kinase-dead receptor retains specific FGF-binding capability.","evidence":"Recombinant Fc-fusion binding assay with purified ligands","pmids":["11418238"],"confidence":"High","gaps":["Binding affinity not quantitatively measured","Full ligand spectrum not tested","Cellular consequence of binding unknown"]},{"year":2003,"claim":"Showing that FGFRL1 localizes to the plasma membrane and inhibits cell proliferation upon overexpression provided the first functional evidence for a decoy receptor mechanism.","evidence":"GFP fusion localization, heparin/FGF2 binding assays, and proliferation assay in MG-63 cells","pmids":["12813049"],"confidence":"High","gaps":["Decoy mechanism not directly demonstrated in signaling pathway terms","No loss-of-function data"]},{"year":2007,"claim":"Fgfrl1 knockout mice dying perinatally from diaphragm deficiency established the first essential in vivo function, showing this receptor is not merely redundant with classical FGFRs.","evidence":"Targeted gene knockout in mice with histological and molecular analysis","pmids":["17986259"],"confidence":"High","gaps":["Molecular mechanism underlying diaphragm defect unknown","Cell-type-specific requirements not resolved"]},{"year":2007,"claim":"Discovery that FGFRL1 forms constitutive homodimers and promotes heparan-sulfate-dependent cell adhesion revealed a ligand-independent adhesion function distinct from classical FGFR signaling.","evidence":"FRET, co-precipitation, cell adhesion assays with heparin competition and heparin-binding-site mutagenesis","pmids":["18061161"],"confidence":"High","gaps":["In vivo relevance of adhesion function not tested","Identity of trans-binding partner on opposing cell unknown"]},{"year":2008,"claim":"A human frameshift mutation in FGFRL1 causing craniosynostosis, combined with identification of two intracellular sorting motifs, revealed that intracellular trafficking controls receptor surface density and linked FGFRL1 to human craniofacial disease.","evidence":"Subcellular localization by fluorescence microscopy and deletion mutagenesis of patient mutation","pmids":["19056490"],"confidence":"High","gaps":["Mechanism by which altered surface retention causes craniosynostosis not established","Single family reported"]},{"year":2009,"claim":"Broad FGF-ligand profiling, quantitative binding data, and in vivo epistasis in Xenopus formally established the decoy receptor model: shed or membrane-bound FGFRL1 sequesters FGFs to antagonize canonical FGFR signaling.","evidence":"Ligand dot blot, cell-based binding, surface plasmon resonance, and ectopic expression in Xenopus embryos","pmids":["19920134"],"confidence":"High","gaps":["Relative contribution of shed vs. membrane-bound decoy function in vivo unclear","Protease responsible for ectodomain shedding unidentified"]},{"year":2009,"claim":"Fgfrl1 knockout mice lacking kidneys due to failed ureteric branching and mesenchymal-to-epithelial transition, combined with recapitulation of Wolf-Hirschhorn syndrome features, expanded the essential in vivo roles to nephrogenesis, craniofacial, and cardiac development.","evidence":"Targeted knockout with in situ hybridization, marker analysis, and comprehensive phenotypic characterization","pmids":["19715689","19383940"],"confidence":"High","gaps":["Cell-autonomous vs. non-autonomous role in nephron progenitors not distinguished","Downstream signaling pathway in kidney unknown"]},{"year":2009,"claim":"Quantitative measurement of zinc binding by the histidine-rich intracellular tail (~2.6 Zn²⁺/mol) identified a novel zinc-binding module, suggesting a metal-dependent function for the cytoplasmic domain.","evidence":"Recombinant protein atomic absorption spectroscopy with evolutionary comparison to sea urchin ortholog","pmids":["20021659"],"confidence":"High","gaps":["Functional consequence of zinc binding unknown","Whether zinc binding regulates trafficking or partner interactions untested"]},{"year":2010,"claim":"Discovery that FGFRL1 induces cell–cell fusion into multinucleated syncytia, requiring only Ig3 and the transmembrane domain, uncovered a fusogenic activity unprecedented among Ig-superfamily receptors.","evidence":"Overexpression in CHO/HEK293/HeLa cells with luciferase/GFP cytoplasmic mixing reporters and domain deletions","pmids":["20851884"],"confidence":"High","gaps":["In vivo tissue where fusion occurs not identified","Whether fusion is homotypic or heterotypic in vivo unknown"]},{"year":2011,"claim":"Identification of Spred1/Sprouty family members as intracellular binding partners of the histidine-rich tail connected FGFRL1 to Ras/MAPK pathway regulation and showed Spred1 increases receptor surface retention.","evidence":"Yeast two-hybrid, co-precipitation, co-localization in COS1/HEK293 cells, truncation analysis","pmids":["21616146"],"confidence":"High","gaps":["Functional consequence of Spred1 interaction for MAPK signaling output not directly tested","In vivo relevance not confirmed"]},{"year":2013,"claim":"In beta-cells, FGFRL1 activates ERK1/2 in a ligand-independent manner via SHP-1 phosphatase recruitment to its SH2-binding motif, demonstrating that the kinase-dead receptor can transduce intracellular signals through adaptor/phosphatase interactions.","evidence":"Co-immunoprecipitation, domain deletion/point mutation, ERK1/2 phosphorylation assay, localization to insulin granules","pmids":["23640895"],"confidence":"High","gaps":["Contradicted by later study finding no ERK effect in other cell types","SHP-1 interaction not validated in vivo"]},{"year":2014,"claim":"Domain-specific in vivo analysis established that the entire intracellular domain is dispensable for diaphragm and kidney development, definitively assigning essential functions to the extracellular region and resolving apparent contradictions with cell-based signaling studies.","evidence":"Knock-in mouse replacing intracellular domain with GFP, comprehensive phenotypic evaluation; concurrent KO showing slow muscle fiber loss","pmids":["25126760","25172430"],"confidence":"High","gaps":["How the extracellular domain signals for slow fiber specification unknown","Slight glomerular reduction in knock-in mice not explained"]},{"year":2015,"claim":"Mapping the fusogenic determinant to a hydrophobic β-sheet site on Ig3, where single amino acid mutations abolish fusion, defined the molecular basis of FGFRL1-mediated cell fusion at residue-level resolution.","evidence":"Point mutagenesis, inhibition by soluble Ig1-2-3 and anti-Ig3 monoclonal antibodies, computational modeling","pmids":["26025674"],"confidence":"High","gaps":["Structural mechanism of membrane merger not resolved","No crystal structure of Ig3 available"]},{"year":2016,"claim":"Systematic gain- and loss-of-function experiments found no effect on proliferation or ERK1/2 signaling but confirmed adhesion-promoting activity, repositioning FGFRL1 as primarily a cell adhesion molecule rather than a canonical signaling receptor.","evidence":"TetOn-inducible overexpression, siRNA knockdown, Kinexus antibody microarray for 250 signaling proteins, adhesion assays","pmids":["27220341"],"confidence":"High","gaps":["Discrepancy with beta-cell ERK activation data not fully resolved","Adhesion partner on opposing cell still unidentified"]},{"year":2017,"claim":"Evolutionary analysis showed fusogenic Ig3 activity emerged in vertebrates through acquisition of specific hydrophobic residues, as four mutations converted non-fusogenic invertebrate/fish-duplicate Ig3 into a fusogen, revealing the molecular evolutionary origin of this function.","evidence":"Comparative Ig3 domain expression from multiple species, CHO cell fusion assay, gain-of-function mutagenesis","pmids":["28596102"],"confidence":"High","gaps":["Selective advantage of fusogenic activity in vertebrate evolution unclear","In vivo fusion target tissue still unidentified"]},{"year":2018,"claim":"Demonstration that FGFRL1 forms 2:1 heterocomplexes with FGFR1 that assemble into 4:2 signaling units upon FGF2 stimulation established a co-receptor mechanism, explaining how a kinase-dead receptor can modulate FGFR1 signaling output in beta-cells.","evidence":"Reciprocal co-immunoprecipitation, quantitative live-cell molecular interaction imaging, siRNA knockdown, survival assay","pmids":["30217817"],"confidence":"High","gaps":["Whether FGFRL1-FGFR1 heterocomplexes form in non-beta-cell contexts unknown","Stoichiometry not confirmed by structural methods"]},{"year":2020,"claim":"Ig2 was identified as the primary high-affinity FGF8-binding domain (KD ~2–3 nM), while systematic domain-specific knockouts showed Ig3 is essential for kidney formation and Ig2 contributes to kidney size, assigning distinct in vivo roles to individual extracellular domains.","evidence":"Recombinant domain SPR binding assays; domain-specific knockout mice with histological analysis","pmids":["33019532","31923383"],"confidence":"High","gaps":["Whether Ig3 kidney function is mediated by fusion, adhesion, or ligand binding is unresolved","Ig3 binding partners in metanephric mesenchyme unknown"]},{"year":2022,"claim":"Functional studies in beta-cells showed FGFRL1 enhances glucose-stimulated NADPH metabolism, insulin secretion, and maturity marker expression through the FGFR5/FGFR1 complex, with a truncated isoform acting as a dominant-negative, providing a physiological context for the co-receptor mechanism.","evidence":"Genetically encoded NADPH sensor, overexpression, dominant-negative truncation, insulin secretion and transcript analysis","pmids":["35414066"],"confidence":"High","gaps":["In vivo beta-cell phenotype in Fgfrl1 knockout mice not reported","Whether laminin-FGFRL1 axis operates in islet development unknown"]},{"year":null,"claim":"Major open questions include the physiological tissue in which FGFRL1-mediated cell fusion occurs, the identity of the ectodomain shedding protease, the structural basis of Ig3-mediated fusion, and whether the co-receptor and decoy-receptor mechanisms operate in the same or different developmental contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of FGFRL1","In vivo fusion target tissue unidentified","Ectodomain shedding protease unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,6,17]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[4,16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[11,12,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,4,5,12,17]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[5,12]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,12,17,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,7,8,13,19]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[4,10,15,16]}],"complexes":["FGFRL1 homodimer/homotrimer","FGFRL1:FGFR1 heterocomplex (2:1)"],"partners":["FGFR1","SHP-1","SPRED1","FGF2","FGF8","ENO1"],"other_free_text":[]},"mechanistic_narrative":"FGFRL1 (FGFR5) is a transmembrane receptor structurally related to classical FGFRs but lacking an intracellular tyrosine kinase domain, functioning instead as a modulator of FGF signaling, a cell adhesion molecule, and a cell fusogen. Its three extracellular Ig-like domains bind FGF ligands (FGF2, FGF3, FGF4, FGF8, FGF10, FGF22) and heparin with high affinity—Ig2 is the primary FGF8-binding site and Ig3 is essential for metanephric kidney formation and mediates cell–cell fusion through a hydrophobic β-sheet site that evolved fusogenic capacity in vertebrates [PMID:19920134, PMID:33019532, PMID:31923383, PMID:20851884, PMID:28596102]. FGFRL1 forms constitutive homodimers/homotrimers and assembles into 2:1 heterocomplexes with FGFR1 to function as a co-receptor that promotes beta-cell glucose metabolism, insulin secretion, and survival, while its shed ectodomain can antagonize FGF signaling as a decoy receptor [PMID:30217817, PMID:35414066, PMID:19920134]. Loss of Fgfrl1 in mice causes perinatal lethality with diaphragm aplasia, kidney agenesis, craniofacial dysgenesis, and loss of slow muscle fibers, recapitulating features of Wolf-Hirschhorn syndrome [PMID:17986259, PMID:19383940, PMID:25172430]."},"prefetch_data":{"uniprot":{"accession":"Q8N441","full_name":"Fibroblast growth factor receptor-like 1","aliases":["FGF homologous factor receptor","FGFR-like protein","Fibroblast growth factor receptor 5","FGFR-5"],"length_aa":504,"mass_kda":54.5,"function":"Has a negative effect on cell proliferation","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q8N441/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGFRL1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGFRL1","total_profiled":1310},"omim":[{"mim_id":"605830","title":"FIBROBLAST GROWTH FACTOR RECEPTOR-LIKE 1; FGFRL1","url":"https://www.omim.org/entry/605830"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FGFRL1"},"hgnc":{"alias_symbol":["FGFR5"],"prev_symbol":[]},"alphafold":{"accession":"Q8N441","domains":[{"cath_id":"2.60.40.10","chopping":"31-118","consensus_level":"high","plddt":85.2617,"start":31,"end":118},{"cath_id":"2.60.40.10","chopping":"146-240","consensus_level":"high","plddt":83.1206,"start":146,"end":240},{"cath_id":"2.60.40.10","chopping":"248-357","consensus_level":"high","plddt":86.6938,"start":248,"end":357}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N441","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N441-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N441-F1-predicted_aligned_error_v6.png","plddt_mean":71.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGFRL1","jax_strain_url":"https://www.jax.org/strain/search?query=FGFRL1"},"sequence":{"accession":"Q8N441","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N441.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N441/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N441"}},"corpus_meta":[{"pmid":"11418238","id":"PMC_11418238","title":"Identification of a new fibroblast growth factor receptor, FGFR5.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11418238","citation_count":214,"is_preprint":false},{"pmid":"21044961","id":"PMC_21044961","title":"MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21044961","citation_count":170,"is_preprint":false},{"pmid":"11031111","id":"PMC_11031111","title":"Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11031111","citation_count":127,"is_preprint":false},{"pmid":"21080029","id":"PMC_21080029","title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor.","date":"2010","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/21080029","citation_count":121,"is_preprint":false},{"pmid":"32396269","id":"PMC_32396269","title":"Lung CSC-derived exosomal miR-210-3p contributes to a pro-metastatic phenotype in lung cancer by targeting FGFRL1.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32396269","citation_count":81,"is_preprint":false},{"pmid":"12813049","id":"PMC_12813049","title":"Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12813049","citation_count":67,"is_preprint":false},{"pmid":"19383940","id":"PMC_19383940","title":"Multiple congenital malformations of Wolf-Hirschhorn syndrome are recapitulated in Fgfrl1 null mice.","date":"2009","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19383940","citation_count":66,"is_preprint":false},{"pmid":"19920134","id":"PMC_19920134","title":"The FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19920134","citation_count":55,"is_preprint":false},{"pmid":"31919528","id":"PMC_31919528","title":"Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/31919528","citation_count":53,"is_preprint":false},{"pmid":"19715689","id":"PMC_19715689","title":"The murine Fgfrl1 receptor is essential for the development of the metanephric kidney.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19715689","citation_count":48,"is_preprint":false},{"pmid":"17986259","id":"PMC_17986259","title":"Mice with a targeted disruption of the Fgfrl1 gene die at birth due to alterations in the diaphragm.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17986259","citation_count":48,"is_preprint":false},{"pmid":"23112089","id":"PMC_23112089","title":"Role of FGFRL1 and other FGF signaling proteins in early kidney development.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/23112089","citation_count":46,"is_preprint":false},{"pmid":"17011755","id":"PMC_17011755","title":"An essential role for zebrafish Fgfrl1 during gill cartilage development.","date":"2006","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/17011755","citation_count":45,"is_preprint":false},{"pmid":"23640895","id":"PMC_23640895","title":"Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23640895","citation_count":42,"is_preprint":false},{"pmid":"31957179","id":"PMC_31957179","title":"FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31957179","citation_count":40,"is_preprint":false},{"pmid":"18061161","id":"PMC_18061161","title":"The cell surface receptor FGFRL1 forms constitutive dimers that promote cell adhesion.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18061161","citation_count":39,"is_preprint":false},{"pmid":"19056490","id":"PMC_19056490","title":"Characterization of the first FGFRL1 mutation identified in a craniosynostosis patient.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19056490","citation_count":38,"is_preprint":false},{"pmid":"16525717","id":"PMC_16525717","title":"Expression of FGFRL1, a novel fibroblast growth factor receptor, during embryonic development.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16525717","citation_count":37,"is_preprint":false},{"pmid":"28923346","id":"PMC_28923346","title":"Role of fibroblast growth factor receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal cell differentiation to osteoblasts and adipocytes.","date":"2017","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28923346","citation_count":36,"is_preprint":false},{"pmid":"30217817","id":"PMC_30217817","title":"Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30217817","citation_count":34,"is_preprint":false},{"pmid":"11566361","id":"PMC_11566361","title":"The mouse Fgfrl1 gene coding for a novel FGF receptor-like protein.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11566361","citation_count":30,"is_preprint":false},{"pmid":"25172430","id":"PMC_25172430","title":"The FgfrL1 receptor is required for development of slow muscle fibers.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25172430","citation_count":28,"is_preprint":false},{"pmid":"38134594","id":"PMC_38134594","title":"Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38134594","citation_count":27,"is_preprint":false},{"pmid":"20851884","id":"PMC_20851884","title":"Rapid fusion and syncytium formation of heterologous cells upon expression of the FGFRL1 receptor.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20851884","citation_count":27,"is_preprint":false},{"pmid":"15652159","id":"PMC_15652159","title":"Fish possess multiple copies of fgfrl1, the gene for a novel FGF receptor.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15652159","citation_count":25,"is_preprint":false},{"pmid":"30008923","id":"PMC_30008923","title":"miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30008923","citation_count":21,"is_preprint":false},{"pmid":"19740411","id":"PMC_19740411","title":"FGFRL1 is a neglected putative actor of the FGF signalling pathway present in all major metazoan phyla.","date":"2009","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/19740411","citation_count":21,"is_preprint":false},{"pmid":"20024584","id":"PMC_20024584","title":"Examination of FGFRL1 as a candidate gene for diaphragmatic defects at chromosome 4p16.3 shows that Fgfrl1 null mice have reduced expression of Tpm3, sarcomere genes and Lrtm1 in the diaphragm.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20024584","citation_count":21,"is_preprint":false},{"pmid":"16273302","id":"PMC_16273302","title":"Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors.","date":"2005","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16273302","citation_count":18,"is_preprint":false},{"pmid":"21616146","id":"PMC_21616146","title":"Interaction of the receptor FGFRL1 with the negative regulator Spred1.","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21616146","citation_count":18,"is_preprint":false},{"pmid":"27220341","id":"PMC_27220341","title":"Receptor FGFRL1 does not promote cell proliferation but induces cell adhesion.","date":"2016","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27220341","citation_count":18,"is_preprint":false},{"pmid":"29675438","id":"PMC_29675438","title":"FGFRL1 Promotes Ovarian Cancer Progression by Crosstalk with Hedgehog Signaling.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29675438","citation_count":15,"is_preprint":false},{"pmid":"20021659","id":"PMC_20021659","title":"Comparison of the receptor FGFRL1 from sea urchins and humans illustrates evolution of a zinc binding motif in the intracellular domain.","date":"2009","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20021659","citation_count":14,"is_preprint":false},{"pmid":"25126760","id":"PMC_25126760","title":"Targeted disruption of the intracellular domain of receptor FgfrL1 in mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25126760","citation_count":14,"is_preprint":false},{"pmid":"23775577","id":"PMC_23775577","title":"An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer.","date":"2013","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23775577","citation_count":13,"is_preprint":false},{"pmid":"16887372","id":"PMC_16887372","title":"Fgfrl1, a fibroblast growth factor receptor-like gene, is found in the cephalochordate Branchiostoma floridae but not in the urochordate Ciona intestinalis.","date":"2006","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16887372","citation_count":12,"is_preprint":false},{"pmid":"23136609","id":"PMC_23136609","title":"Genome-wide comparison of FGFRL1 with structurally related surface receptors.","date":"2010","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23136609","citation_count":12,"is_preprint":false},{"pmid":"35980984","id":"PMC_35980984","title":"FGFRL1 and FGF genes are associated with height, hypertension, and osteoporosis.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35980984","citation_count":11,"is_preprint":false},{"pmid":"33019532","id":"PMC_33019532","title":"Dissecting the Interaction of FGF8 with Receptor FGFRL1.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33019532","citation_count":11,"is_preprint":false},{"pmid":"26025674","id":"PMC_26025674","title":"Cell-cell fusion induced by the Ig3 domain of receptor FGFRL1 in CHO cells.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26025674","citation_count":11,"is_preprint":false},{"pmid":"31923383","id":"PMC_31923383","title":"Functional domains of the FgfrL1 receptor.","date":"2020","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31923383","citation_count":9,"is_preprint":false},{"pmid":"20938900","id":"PMC_20938900","title":"Downregulation of FGFRL1 contributes to the development of the diaphragmatic defect in the nitrofen model of congenital diaphragmatic hernia.","date":"2010","source":"European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie","url":"https://pubmed.ncbi.nlm.nih.gov/20938900","citation_count":9,"is_preprint":false},{"pmid":"24026051","id":"PMC_24026051","title":"Evidence that the novel receptor FGFRL1 signals indirectly via FGFR1.","date":"2013","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24026051","citation_count":8,"is_preprint":false},{"pmid":"33443296","id":"PMC_33443296","title":"Evidence that FGFRL1 contributes to congenital diaphragmatic hernia development in humans.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/33443296","citation_count":8,"is_preprint":false},{"pmid":"28101211","id":"PMC_28101211","title":"Receptor FGFRL1 acts as a tumor suppressor in nude mice when overexpressed in HEK 293 Tet-On cells.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28101211","citation_count":8,"is_preprint":false},{"pmid":"29241927","id":"PMC_29241927","title":"Prenatal diagnosis of a 1.6-Mb 4p16.3 interstitial microdeletion encompassing FGFRL1 and TACC3 associated with bilateral cleft lip and palate of Wolf-Hirschhorn syndrome facial dysmorphism and short long bones.","date":"2017","source":"Taiwanese journal of obstetrics & gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/29241927","citation_count":8,"is_preprint":false},{"pmid":"36629784","id":"PMC_36629784","title":"Distinct effects of SDC3 and FGFRL1 on selective neurodegeneration in AD and PD.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36629784","citation_count":7,"is_preprint":false},{"pmid":"35053442","id":"PMC_35053442","title":"Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35053442","citation_count":7,"is_preprint":false},{"pmid":"29963148","id":"PMC_29963148","title":"FGFRL1 deficiency reduces motility and tumorigenic potential of cells derived from oesophageal squamous cell carcinomas.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29963148","citation_count":6,"is_preprint":false},{"pmid":"28596102","id":"PMC_28596102","title":"Evolution of the fusogenic activity of the receptor FGFRL1.","date":"2017","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/28596102","citation_count":6,"is_preprint":false},{"pmid":"25506393","id":"PMC_25506393","title":"Interstitial 287 kb deletion of 4p16.3 including FGFRL1 gene associated with language impairment and overgrowth.","date":"2014","source":"Molecular cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25506393","citation_count":6,"is_preprint":false},{"pmid":"35414066","id":"PMC_35414066","title":"Laminin matrix regulates beta-cell FGFR5 expression to enhance glucose-stimulated metabolism.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35414066","citation_count":5,"is_preprint":false},{"pmid":"36160905","id":"PMC_36160905","title":"HuR affects chemoresistance of small cell lung cancer by regulating FGFRL1 expression.","date":"2022","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36160905","citation_count":4,"is_preprint":false},{"pmid":"37062273","id":"PMC_37062273","title":"Downregulation of miR-210-3p Attenuates High Glucose-Induced Angiogenesis of Vascular Endothelial Cells via Targeting FGFRL1.","date":"2023","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/37062273","citation_count":4,"is_preprint":false},{"pmid":"21980560","id":"PMC_21980560","title":"A net-like structure with pores is observed during cell fusion induced by the receptor FGFRL1.","date":"2011","source":"Communicative & integrative biology","url":"https://pubmed.ncbi.nlm.nih.gov/21980560","citation_count":4,"is_preprint":false},{"pmid":"40699684","id":"PMC_40699684","title":"FGFRL1: Structure, Molecular Function, and Involvement in Human Disease.","date":"2025","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/40699684","citation_count":3,"is_preprint":false},{"pmid":"37116156","id":"PMC_37116156","title":"Aberrant Expression of FGFRL1 in Esophageal Cancer and Its Regulation by miR-107.","date":"2023","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/37116156","citation_count":2,"is_preprint":false},{"pmid":"25934085","id":"PMC_25934085","title":"Phylogenetic analysis of receptor FgfrL1 shows divergence of the C-terminal end in rodents.","date":"2015","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25934085","citation_count":2,"is_preprint":false},{"pmid":"37693980","id":"PMC_37693980","title":"Suppression of Fibroblast Growth Factor Receptor-5 (FGFR5) has no Impact on Axon Regeneration after SCI.","date":"2023","source":"Journal of pharmacy & bioallied sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37693980","citation_count":1,"is_preprint":false},{"pmid":"35365991","id":"PMC_35365991","title":"[Overexpression of fibroblast growth factor receptor like 1 (FGFRL1) inhibits proliferation and migration of HCT116 human colon cancer cells, and promotes their apoptosis].","date":"2022","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35365991","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":29576,"output_tokens":5201,"usd":0.083372},"stage2":{"model":"claude-opus-4-6","input_tokens":8757,"output_tokens":4270,"usd":0.225802},"total_usd":0.309174,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"FGFRL1 is an integral membrane protein with three extracellular Ig-like domains, a transmembrane segment, and a short intracellular domain that lacks any protein tyrosine kinase domain, distinguishing it from classical FGFRs.\",\n      \"method\": \"Subtractive cDNA cloning, structural analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original structural characterization, replicated by multiple subsequent studies\",\n      \"pmids\": [\"11031111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Recombinant FGFRL1 (FGFR5) ectodomain binds FGF-2 specifically but not FGF-7 or EGF, and with lower affinity than cognate FGFR2C.\",\n      \"method\": \"Recombinant Fc-fusion protein binding assay\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding assay with recombinant protein, replicated by later studies\",\n      \"pmids\": [\"11418238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FGFRL1 localizes to the plasma membrane when expressed as a GFP fusion protein in cultured cells, interacts specifically with heparin and FGF2, and exerts a negative effect on cell proliferation when overexpressed in MG-63 osteosarcoma cells, consistent with a decoy receptor function.\",\n      \"method\": \"GFP fusion live-cell localization, baculovirus recombinant protein production, heparin and FGF2 binding assays, proliferation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods in a single study\",\n      \"pmids\": [\"12813049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Targeted disruption of the Fgfrl1 gene in mice causes perinatal death due to a significantly reduced diaphragm muscle, demonstrating an essential role of FGFRL1 in diaphragm development.\",\n      \"method\": \"Targeted gene knockout in mice, histological and molecular analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with specific developmental phenotype, replicated by subsequent studies\",\n      \"pmids\": [\"17986259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGFRL1 forms constitutive homodimers at the cell surface as demonstrated by FRET and co-precipitation, and its extracellular domain promotes cell adhesion mediated by heparan sulfate glycosaminoglycans; adhesion is blocked by soluble heparin and reduced by mutagenesis of the heparin-binding site.\",\n      \"method\": \"FRET, co-precipitation, cell adhesion assay, in vitro mutagenesis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis and functional assays\",\n      \"pmids\": [\"18061161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A human FGFRL1 frameshift mutation causing craniosynostosis alters subcellular localization: mutant FGFRL1 is retained predominantly at the plasma membrane rather than in vesicular/Golgi structures as seen for wild-type; two intracellular motifs (tandem tyrosine-based motif and histidine-rich sequence) are responsible for this differential distribution.\",\n      \"method\": \"Reporter gene assay, subcellular localization by fluorescence microscopy, deletion mutagenesis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — orthogonal methods including mutagenesis and functional reporter assay with patient mutation\",\n      \"pmids\": [\"19056490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The FGFRL1 ectodomain is shed from the cell membrane by an unidentified protease. The soluble ectodomain and membrane-bound receptor bind multiple FGF ligands (FGF2, FGF3, FGF4, FGF8, FGF10, FGF22) with high affinity. Ectopic expression of FGFRL1 in Xenopus embryos antagonizes FGFR signaling, supporting a decoy receptor mechanism.\",\n      \"method\": \"Ligand dot blot, cell-based binding assay, surface plasmon resonance, Xenopus ectopic expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical methods plus in vivo epistasis in Xenopus\",\n      \"pmids\": [\"19920134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fgfrl1-deficient mice fail to develop the metanephric kidney due to a dramatic reduction in ureteric branching morphogenesis and lack of mesenchymal-to-epithelial transition; markers Wnt4, Fgf8, Pax8, and Lim1 are absent from the metanephric mesenchyme, and apoptosis is increased in the cortical zone.\",\n      \"method\": \"Targeted gene knockout, in situ hybridization, marker gene expression analysis, histology\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotype, replicated by subsequent studies\",\n      \"pmids\": [\"19715689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Targeted deletion of mouse Fgfrl1 recapitulates multiple Wolf-Hirschhorn syndrome phenotypes including craniofacial dysgenesis, skeletal anomalies, congenital heart defects, transient fetal anemia, and a fully penetrant diaphragm defect, establishing Fgfrl1 insufficiency as a contributor to WHS.\",\n      \"method\": \"Targeted gene knockout in mice, phenotypic analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with comprehensive phenotypic characterization\",\n      \"pmids\": [\"19383940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The intracellular histidine-rich domain of human FGFRL1 binds zinc, with approximately 2.6 moles zinc per mole protein as measured by atomic absorption; the sea urchin ortholog with a shorter histidine-rich motif binds less zinc (~1.7 mol/mol), indicating evolutionary shaping of a novel zinc-binding domain.\",\n      \"method\": \"Recombinant protein production, nickel/zinc affinity chromatography, atomic absorption spectroscopy\",\n      \"journal\": \"BMC biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical measurement of zinc binding with comparative evolutionary analysis\",\n      \"pmids\": [\"20021659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FGFRL1 induces rapid fusion of cultured cells (CHO, HEK293, HeLa) into large multinucleated syncytia; the Ig3 domain and transmembrane domain are both necessary and sufficient for this fusogenic activity, as demonstrated by luciferase and GFP reporter assays for cytoplasmic mixing.\",\n      \"method\": \"Overexpression in CHO/HEK293/HeLa cells, luciferase/GFP reporter cytoplasmic mixing assays, domain deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reconstitution with reporter assays and domain mapping\",\n      \"pmids\": [\"20851884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGFRL1 binds with its C-terminal histidine-rich domain to Spred1 and other Sprouty/Spred family members (negative regulators of the Ras/Raf/Erk pathway); interaction is via the SPR domain of Spred1, verified by yeast two-hybrid, co-precipitation, and co-distribution at the plasma membrane. Spred1 increases FGFRL1 retention at the plasma membrane.\",\n      \"method\": \"Yeast two-hybrid, co-precipitation, co-localization in COS1 and HEK293 cells, truncation analysis\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction verified by multiple methods\",\n      \"pmids\": [\"21616146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In pancreatic beta-cells, FGFRL1 localizes both to the plasma membrane and intracellular insulin secretory granules. It induces ligand-independent ERK1/2 activation via interaction of its intracellular SH2-binding motif with SHP-1 phosphatase; deletion of the histidine-rich domain or full intracellular sequence reduces ERK1/2 activation and shifts localization to the plasma membrane. Overexpression increases cellular insulin content and matrix adhesion.\",\n      \"method\": \"Fluorescent protein tagging, live-cell imaging, co-immunoprecipitation, domain deletion and point mutation analysis, ERK1/2 phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, mutagenesis, binding partner identification\",\n      \"pmids\": [\"23640895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FgfrL1-deficient mice lack slow muscle fibers (marked by Myh7, Myl2, Myl3) in the diaphragm and other slow-fiber-rich muscles at E18.5, while fast fiber markers are unaffected; this phenotype is not caused by kidney agenesis, establishing a specific role of FgfrL1 in embryonic slow muscle fiber development.\",\n      \"method\": \"Gene array, qPCR, in situ hybridization, genetic epistasis (Wnt4 KO comparison)\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO phenotype with molecular markers and epistasis control\",\n      \"pmids\": [\"25172430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mice lacking the conserved intracellular domain motifs of FgfrL1 (dileucine, tandem tyrosine-based motif YXXΦ, histidine-rich sequence) replaced by GFP are viable, fertile, and phenotypically normal (with only a slight reduction in glomeruli), demonstrating that the extracellular domain, not the intracellular domain, conducts the essential functions of FgfrL1.\",\n      \"method\": \"Knock-in mouse model (FgfrL1ΔC-GFP), phenotypic analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knock-in with comprehensive phenotypic evaluation\",\n      \"pmids\": [\"25126760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cell-cell fusion induced by FGFRL1 requires a hydrophobic site on the Ig3 domain located on a β-sheet within a β-barrel; single amino acid mutations at this site abolish fusion, and soluble Ig1-Ig2-Ig3 or monoclonal antibodies against Ig3 inhibit fusion.\",\n      \"method\": \"Mutational analysis, inhibition by soluble proteins and antibodies, computer modeling\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis with functional assay, multiple inhibition strategies\",\n      \"pmids\": [\"26025674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FGFRL1 has no effect on cell proliferation or ERK1/2 activation in overexpression or siRNA knockdown experiments, but promotes cell adhesion during the initial hours after seeding, suggesting it functions as a cell adhesion protein similar to nectins rather than a signaling receptor.\",\n      \"method\": \"TetOn-inducible overexpression, siRNA knockdown, proliferation assay, Kinexus antibody microarray (250 signaling proteins), cell adhesion assay\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches with gain- and loss-of-function\",\n      \"pmids\": [\"27220341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FGFR5 (FGFRL1) forms ligand-independent homodimers (~25%) and homotrimers (~75%) at the plasma membrane, and co-expressed with FGFR1 forms heterocomplexes with a 2:1 FGFR5:FGFR1 ratio; upon FGF2 stimulation, these form 4:2 signaling complexes. FGFR5 acts as a co-receptor for FGFR1 and promotes beta-cell survival.\",\n      \"method\": \"Co-immunoprecipitation, quantitative live-cell imaging (molecular interaction measurements), siRNA knockdown, survival assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus quantitative live-cell imaging, multiple functional assays\",\n      \"pmids\": [\"30217817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The Ig2 domain of FGFRL1 is the primary binding site for FGF8; all FGFRL1 constructs containing Ig2 interact with FGF8 with high affinity (KD ~2-3 nM by surface plasmon resonance), while constructs lacking Ig2 poorly interact, establishing FGFRL1 as a physiological high-affinity receptor for FGF8.\",\n      \"method\": \"Recombinant domain expression, ELISA, surface plasmon resonance (Biacore)\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic domain dissection with quantitative in vitro binding assays\",\n      \"pmids\": [\"33019532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FgfrL1 domain-specific knockout mice reveal that the Ig3 domain is essential for metanephric kidney formation (Ig3-deficient mice completely lack kidneys), the Ig2 domain contributes to kidney growth (Ig2-deficient mice have substantially smaller kidneys), and the intracellular domain and Ig1 domain are dispensable for kidney and diaphragm development.\",\n      \"method\": \"Domain-specific knockout mice, histological and phenotypic analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic domain-deletion mouse genetics with defined organ phenotypes\",\n      \"pmids\": [\"31923383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGFRL1 interacts with ENO1 and regulates the ENO1-PI3K/Akt signaling pathway to modulate chemoresistance in small-cell lung cancer; knockdown of FGFRL1 increases chemosensitivity through increased apoptosis and cell cycle arrest.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, Western blotting, cell viability assay\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP of binding partner plus functional KD phenotype, single lab\",\n      \"pmids\": [\"31957179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The fusogenic activity of FGFRL1 Ig3 domain evolved during vertebrate evolution; Ig3 domains from humans, mice, chicken, and fish fuse CHO cells while those from lancelet and sea urchin do not. Mutagenesis of four amino acids in a hydrophobic pocket of the non-fusogenic fish FGFRL1b Ig3 converts it to a fusogenic protein.\",\n      \"method\": \"Comparative Ig3 domain expression, cell fusion assay, chimeric constructs, in vitro mutagenesis\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional rescue demonstrates specific residues required for fusogenic activity\",\n      \"pmids\": [\"28596102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Overexpression of FGFR5 (FGFRL1) in beta-cells enhances glucose-stimulated NADPH metabolism and insulin secretion, and increases expression of glycolytic enzymes (GCK, PKM2) and maturity marker UCN3; this response is disrupted by a truncated receptor isoform (R5ΔC) that inhibits the FGFR5/FGFR1 signaling complex, and laminin-induced upregulation of endogenous FGFR5 similarly enhances glucose metabolism.\",\n      \"method\": \"Genetically encoded NADPH/NADP+ sensor (Apollo-NADP+), overexpression, dominant-negative truncation, insulin secretion assay, transcript analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple functional assays with orthogonal readouts and dominant-negative validation\",\n      \"pmids\": [\"35414066\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGFRL1 is a single-pass transmembrane receptor with three extracellular Ig-like domains that binds FGF ligands (especially FGF2, FGF8) and heparin with high affinity via the Ig2 and Ig3 domains; it lacks an intracellular tyrosine kinase domain and instead carries a histidine-rich zinc-binding tail that interacts with SHP-1 phosphatase and Spred1/Sprouty proteins; it forms constitutive homodimers and can act as a co-receptor for FGFR1 in a 2:1 complex, and its membrane-bound or shed ectodomain can antagonize FGF signaling as a decoy receptor; additionally, its Ig3 domain and transmembrane segment are sufficient to induce cell-cell fusion into multinucleated syncytia through a hydrophobic site in Ig3, and it promotes cell adhesion via heparan sulfate proteoglycans, while being essential in vivo for diaphragm development (particularly slow muscle fibers), metanephric kidney nephrogenesis (primarily through Ig3), and craniofacial/skeletal formation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FGFRL1 (FGFR5) is a transmembrane receptor structurally related to classical FGFRs but lacking an intracellular tyrosine kinase domain, functioning instead as a modulator of FGF signaling, a cell adhesion molecule, and a cell fusogen. Its three extracellular Ig-like domains bind FGF ligands (FGF2, FGF3, FGF4, FGF8, FGF10, FGF22) and heparin with high affinity—Ig2 is the primary FGF8-binding site and Ig3 is essential for metanephric kidney formation and mediates cell–cell fusion through a hydrophobic β-sheet site that evolved fusogenic capacity in vertebrates [PMID:19920134, PMID:33019532, PMID:31923383, PMID:20851884, PMID:28596102]. FGFRL1 forms constitutive homodimers/homotrimers and assembles into 2:1 heterocomplexes with FGFR1 to function as a co-receptor that promotes beta-cell glucose metabolism, insulin secretion, and survival, while its shed ectodomain can antagonize FGF signaling as a decoy receptor [PMID:30217817, PMID:35414066, PMID:19920134]. Loss of Fgfrl1 in mice causes perinatal lethality with diaphragm aplasia, kidney agenesis, craniofacial dysgenesis, and loss of slow muscle fibers, recapitulating features of Wolf-Hirschhorn syndrome [PMID:17986259, PMID:19383940, PMID:25172430].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of FGFRL1 as a fifth FGFR family member established that a kinase-dead receptor with three Ig domains and a short intracellular tail exists in the FGF signaling system, raising the question of how it functions without catalytic activity.\",\n      \"evidence\": \"Subtractive cDNA cloning and structural domain analysis\",\n      \"pmids\": [\"11031111\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional data on signaling or biological role\", \"Ligand binding not yet tested\", \"Expression pattern not fully characterized\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that the FGFRL1 ectodomain binds FGF2 but not FGF7 or EGF established ligand selectivity, showing this kinase-dead receptor retains specific FGF-binding capability.\",\n      \"evidence\": \"Recombinant Fc-fusion binding assay with purified ligands\",\n      \"pmids\": [\"11418238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinity not quantitatively measured\", \"Full ligand spectrum not tested\", \"Cellular consequence of binding unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that FGFRL1 localizes to the plasma membrane and inhibits cell proliferation upon overexpression provided the first functional evidence for a decoy receptor mechanism.\",\n      \"evidence\": \"GFP fusion localization, heparin/FGF2 binding assays, and proliferation assay in MG-63 cells\",\n      \"pmids\": [\"12813049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Decoy mechanism not directly demonstrated in signaling pathway terms\", \"No loss-of-function data\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Fgfrl1 knockout mice dying perinatally from diaphragm deficiency established the first essential in vivo function, showing this receptor is not merely redundant with classical FGFRs.\",\n      \"evidence\": \"Targeted gene knockout in mice with histological and molecular analysis\",\n      \"pmids\": [\"17986259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism underlying diaphragm defect unknown\", \"Cell-type-specific requirements not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that FGFRL1 forms constitutive homodimers and promotes heparan-sulfate-dependent cell adhesion revealed a ligand-independent adhesion function distinct from classical FGFR signaling.\",\n      \"evidence\": \"FRET, co-precipitation, cell adhesion assays with heparin competition and heparin-binding-site mutagenesis\",\n      \"pmids\": [\"18061161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of adhesion function not tested\", \"Identity of trans-binding partner on opposing cell unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A human frameshift mutation in FGFRL1 causing craniosynostosis, combined with identification of two intracellular sorting motifs, revealed that intracellular trafficking controls receptor surface density and linked FGFRL1 to human craniofacial disease.\",\n      \"evidence\": \"Subcellular localization by fluorescence microscopy and deletion mutagenesis of patient mutation\",\n      \"pmids\": [\"19056490\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which altered surface retention causes craniosynostosis not established\", \"Single family reported\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Broad FGF-ligand profiling, quantitative binding data, and in vivo epistasis in Xenopus formally established the decoy receptor model: shed or membrane-bound FGFRL1 sequesters FGFs to antagonize canonical FGFR signaling.\",\n      \"evidence\": \"Ligand dot blot, cell-based binding, surface plasmon resonance, and ectopic expression in Xenopus embryos\",\n      \"pmids\": [\"19920134\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of shed vs. membrane-bound decoy function in vivo unclear\", \"Protease responsible for ectodomain shedding unidentified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Fgfrl1 knockout mice lacking kidneys due to failed ureteric branching and mesenchymal-to-epithelial transition, combined with recapitulation of Wolf-Hirschhorn syndrome features, expanded the essential in vivo roles to nephrogenesis, craniofacial, and cardiac development.\",\n      \"evidence\": \"Targeted knockout with in situ hybridization, marker analysis, and comprehensive phenotypic characterization\",\n      \"pmids\": [\"19715689\", \"19383940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous vs. non-autonomous role in nephron progenitors not distinguished\", \"Downstream signaling pathway in kidney unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Quantitative measurement of zinc binding by the histidine-rich intracellular tail (~2.6 Zn²⁺/mol) identified a novel zinc-binding module, suggesting a metal-dependent function for the cytoplasmic domain.\",\n      \"evidence\": \"Recombinant protein atomic absorption spectroscopy with evolutionary comparison to sea urchin ortholog\",\n      \"pmids\": [\"20021659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of zinc binding unknown\", \"Whether zinc binding regulates trafficking or partner interactions untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that FGFRL1 induces cell–cell fusion into multinucleated syncytia, requiring only Ig3 and the transmembrane domain, uncovered a fusogenic activity unprecedented among Ig-superfamily receptors.\",\n      \"evidence\": \"Overexpression in CHO/HEK293/HeLa cells with luciferase/GFP cytoplasmic mixing reporters and domain deletions\",\n      \"pmids\": [\"20851884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo tissue where fusion occurs not identified\", \"Whether fusion is homotypic or heterotypic in vivo unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of Spred1/Sprouty family members as intracellular binding partners of the histidine-rich tail connected FGFRL1 to Ras/MAPK pathway regulation and showed Spred1 increases receptor surface retention.\",\n      \"evidence\": \"Yeast two-hybrid, co-precipitation, co-localization in COS1/HEK293 cells, truncation analysis\",\n      \"pmids\": [\"21616146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Spred1 interaction for MAPK signaling output not directly tested\", \"In vivo relevance not confirmed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"In beta-cells, FGFRL1 activates ERK1/2 in a ligand-independent manner via SHP-1 phosphatase recruitment to its SH2-binding motif, demonstrating that the kinase-dead receptor can transduce intracellular signals through adaptor/phosphatase interactions.\",\n      \"evidence\": \"Co-immunoprecipitation, domain deletion/point mutation, ERK1/2 phosphorylation assay, localization to insulin granules\",\n      \"pmids\": [\"23640895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contradicted by later study finding no ERK effect in other cell types\", \"SHP-1 interaction not validated in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Domain-specific in vivo analysis established that the entire intracellular domain is dispensable for diaphragm and kidney development, definitively assigning essential functions to the extracellular region and resolving apparent contradictions with cell-based signaling studies.\",\n      \"evidence\": \"Knock-in mouse replacing intracellular domain with GFP, comprehensive phenotypic evaluation; concurrent KO showing slow muscle fiber loss\",\n      \"pmids\": [\"25126760\", \"25172430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the extracellular domain signals for slow fiber specification unknown\", \"Slight glomerular reduction in knock-in mice not explained\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping the fusogenic determinant to a hydrophobic β-sheet site on Ig3, where single amino acid mutations abolish fusion, defined the molecular basis of FGFRL1-mediated cell fusion at residue-level resolution.\",\n      \"evidence\": \"Point mutagenesis, inhibition by soluble Ig1-2-3 and anti-Ig3 monoclonal antibodies, computational modeling\",\n      \"pmids\": [\"26025674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of membrane merger not resolved\", \"No crystal structure of Ig3 available\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Systematic gain- and loss-of-function experiments found no effect on proliferation or ERK1/2 signaling but confirmed adhesion-promoting activity, repositioning FGFRL1 as primarily a cell adhesion molecule rather than a canonical signaling receptor.\",\n      \"evidence\": \"TetOn-inducible overexpression, siRNA knockdown, Kinexus antibody microarray for 250 signaling proteins, adhesion assays\",\n      \"pmids\": [\"27220341\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Discrepancy with beta-cell ERK activation data not fully resolved\", \"Adhesion partner on opposing cell still unidentified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Evolutionary analysis showed fusogenic Ig3 activity emerged in vertebrates through acquisition of specific hydrophobic residues, as four mutations converted non-fusogenic invertebrate/fish-duplicate Ig3 into a fusogen, revealing the molecular evolutionary origin of this function.\",\n      \"evidence\": \"Comparative Ig3 domain expression from multiple species, CHO cell fusion assay, gain-of-function mutagenesis\",\n      \"pmids\": [\"28596102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selective advantage of fusogenic activity in vertebrate evolution unclear\", \"In vivo fusion target tissue still unidentified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that FGFRL1 forms 2:1 heterocomplexes with FGFR1 that assemble into 4:2 signaling units upon FGF2 stimulation established a co-receptor mechanism, explaining how a kinase-dead receptor can modulate FGFR1 signaling output in beta-cells.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, quantitative live-cell molecular interaction imaging, siRNA knockdown, survival assay\",\n      \"pmids\": [\"30217817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FGFRL1-FGFR1 heterocomplexes form in non-beta-cell contexts unknown\", \"Stoichiometry not confirmed by structural methods\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Ig2 was identified as the primary high-affinity FGF8-binding domain (KD ~2–3 nM), while systematic domain-specific knockouts showed Ig3 is essential for kidney formation and Ig2 contributes to kidney size, assigning distinct in vivo roles to individual extracellular domains.\",\n      \"evidence\": \"Recombinant domain SPR binding assays; domain-specific knockout mice with histological analysis\",\n      \"pmids\": [\"33019532\", \"31923383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ig3 kidney function is mediated by fusion, adhesion, or ligand binding is unresolved\", \"Ig3 binding partners in metanephric mesenchyme unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Functional studies in beta-cells showed FGFRL1 enhances glucose-stimulated NADPH metabolism, insulin secretion, and maturity marker expression through the FGFR5/FGFR1 complex, with a truncated isoform acting as a dominant-negative, providing a physiological context for the co-receptor mechanism.\",\n      \"evidence\": \"Genetically encoded NADPH sensor, overexpression, dominant-negative truncation, insulin secretion and transcript analysis\",\n      \"pmids\": [\"35414066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo beta-cell phenotype in Fgfrl1 knockout mice not reported\", \"Whether laminin-FGFRL1 axis operates in islet development unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the physiological tissue in which FGFRL1-mediated cell fusion occurs, the identity of the ectodomain shedding protease, the structural basis of Ig3-mediated fusion, and whether the co-receptor and decoy-receptor mechanisms operate in the same or different developmental contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of FGFRL1\", \"In vivo fusion target tissue unidentified\", \"Ectodomain shedding protease unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 6, 17]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [4, 16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [11, 12, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 4, 5, 12, 17]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [5, 12]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 12, 17, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 7, 8, 13, 19]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [4, 10, 15, 16]}\n    ],\n    \"complexes\": [\n      \"FGFRL1 homodimer/homotrimer\",\n      \"FGFRL1:FGFR1 heterocomplex (2:1)\"\n    ],\n    \"partners\": [\n      \"FGFR1\",\n      \"SHP-1\",\n      \"SPRED1\",\n      \"FGF2\",\n      \"FGF8\",\n      \"ENO1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}